Status:
COMPLETED
Preliminary Safety and Efficacy of the PDS-1.0 in Patients With Neovascular Age Related Macular Degeneration (AMD)
Lead Sponsor:
Forsight Vision4
Conditions:
Age-Related Macular Degeneration
Eligibility:
All Genders
50+ years
Phase:
PHASE1
Brief Summary
This study will evaluate the preliminary safety and efficacy of PDS 1.0 in patients with neovascular AMD.
Eligibility Criteria
Inclusion
- Diagnosis of CNV secondary to AMD confirmed by fluorescein angiography, not previously treated
- Retinal thickness due to edema of at least 300um in the study eye
- Best corrected visual acuity of 20/40 or worse in the study eye
- Best corrected visual acuity of 20/40 or better in the fellow eye
Exclusion
- Evidence of scarring CNV (e.g. geographic atrophy) in the study eye
- Fibrosis \>75% of lesion area in the study eye
Key Trial Info
Start Date :
August 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2014
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01186432
Start Date
August 1 2010
End Date
April 1 2014
Last Update
March 5 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Riga, Latvia